January 2023: Promising Phase 2 Trial Results, Accelerating Autoimmune Disease Research and Taking a Patient-Centric Approach Globally

Check out the top five things that happened at Horizon in January, including several announcements, employee stories and more.

1. Second Patient Population Responds Well to Dazodalibep as Possible Sj?gren’s Therapy

On Jan. 18, we shared news that our Phase 2 trial evaluating dazodalibep for the treatment of Sj?gren's syndrome met the primary endpoint in the second study population with moderate-to-severe symptoms of dryness, fatigue and pain in the eyes and mouth (the most common Sj?gren’s symptoms). Learn more: https://bit.ly/3Xm5pmr.

2. Accelerating Autoimmune Disease Research Through Strategic Collaborations

Because of the immune system’s complexity, treating autoimmune diseases can be challenging – a reality that Horizon scientists are continuously looking to overcome in cutting-edge ways through strategic partnering. Learn more in this Horizon Stories blog post: https://bit.ly/3CzQdK4.

3. From Chicago to Tokyo, Check Out a Day in the Life of a Young Horizon Communicator

Follow along as Aoi Oyama, a Horizon communications contractor in Deerfield, Ill., takes you on her travels from Chicago to her home country of Japan, where she visited Horizon’s local office in Tokyo to work alongside colleagues there: https://bit.ly/3JiWPkd.

4. 2022 a Year to Remember for Horizon’s #RAREis Program

Horizon’s #RAREis program elevates the voices, faces and experiences of the rare disease community by providing those impacted with access to important resources. And throughout 2022, we were able to learn from, collaborate with and highlight many organizations and people in the rare disease community through our program in new ways. Take a look back at some of our favorite moments from last year: https://bit.ly/3j5Udvm.

5. Horizon’s International Team Takes Patient-Centric Approach Around the Globe

At Horizon, patients are at the center of everything we do. For our team around the globe, it’s personal. Watch to learn more about our international team: https://bit.ly/3wvKO3m.